Updated:
Immunovant
Immunovant, led by Peter Salzmann, develops anti-FcRn antibody therapies for autoimmune diseases — went public in 2019 via reverse merger.
Immunovant
Immunovant was founded in 2018 as a subsidiary of Roivant Sciences, the biotech holding company created by Vivek Ramaswamy. The firm's establishment reflected the Roivant model of assembling a pipeline of late-stage drug candidates in specific therapeutic areas. Immunovant's lead asset, batoclimab, originated from a December 2017 licensing agreement with HanAll Biopharma, a South Korean biotech that had developed the anti-FcRn antibody for autoimmune indications. The company relocated its headquarters from Cary, North Carolina to New York City following its public listing. The company's strategy centers on a single mechanism: inhibiting the neonatal Fc receptor (FcRn) to reduce pathogenic IgG antibodies. Lead indications include myasthenia gravis, thyroid eye disease, and chronic inflammatory demyelinating polyneuropathy. In addition to batoclimab, the firm is advancing IMVT-1402, a next-generation anti-FcRn antibody designed for deeper IgG suppression with a potentially cleaner safety profile. Immunovant operates across North America and Europe, with clinical trial sites spanning multiple countries and a strategic alliance with Roivant that provides shared infrastructure. A pivotal Phase 3 trial for batoclimab in myasthenia gravis read out positive topline results in March 2024, demonstrating statistically significant reductions in IgG levels. Immunovant completed its merger with Health Sciences Acquisitions Corp. in December 2019, raising $233 million in gross proceeds and securing a Nasdaq listing under the ticker IMVT. The company subsequently raised an additional $200 million in a February 2021 public offering, followed by a $461 million follow-on in February 2024 — one of the largest biotech financings that year (per the firm's regulatory filings, 2024). The firm's pipeline remains concentrated, with no near-term diversification away from FcRn inhibition. In January 2025, Immunovant announced accelerated development timelines for IMVT-1402, targeting a registrational program launch by mid-2026, signaling confidence in the molecule's clinical profile and commercial path. Immunovant's structural differentiator is its inherited relationship with the Roivant family of companies, which provides a shared backend for drug development, regulatory affairs, and commercialization without the overhead of a fully independent enterprise. This model allows a publicly traded entity with a single-drug focus to operate leaner than a standalone biotech typically could, while still accessing capital markets directly rather than through a partnership-based royalty structure.
General information
Firm type
Asset Manager
Year founded
2018
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Principals
Peter Salzmann
Chief Executive Officer
Sector focus
Frequently asked questions
What is Immunovant's relationship to Roivant Sciences?
Immunovant was founded as a subsidiary of Roivant Sciences in 2018 and operates within the Roivant family of biotech companies. Roivant maintains a significant equity stake and provides shared infrastructure including drug development, regulatory support, and administrative functions. This structure allows Immunovant to operate as an independent public company while benefiting from centralized resources that reduce overhead costs relative to a standalone biotech.
What autoimmune indications does Immunovant target?
Immunovant targets autoimmune diseases driven by pathogenic IgG antibodies. Lead indications include myasthenia gravis, thyroid eye disease, and chronic inflammatory demyelinating polyneuropathy. The firm's anti-FcRn mechanism is broadly applicable to IgG-mediated diseases, and management has indicated openness to exploring additional indications as clinical data mature.
How does batoclimab differ from IMVT-1402?
Batoclimab was Immunovant's first anti-FcRn antibody, licensed from HanAll Biopharma in 2017. IMVT-1402 is a next-generation molecule engineered for deeper IgG suppression and a potentially improved safety profile, particularly around lipid metabolism markers. The firm has stated it views IMVT-1402 as its lead asset going forward, with batoclimab serving as a clinical proof-of-concept platform that validated the mechanism.
How is Immunovant funded?
Immunovant is funded through public equity markets. The firm went public in December 2019 via a reverse merger with Health Sciences Acquisitions Corp., raising $233 million. It raised $200 million in a February 2021 follow-on offering and an additional $461 million in February 2024 — one of the largest biotech follow-ons of that year. The company does not currently generate product revenue, relying on equity financings to fund its clinical programs.
Does Immunovant participate in co-development partnerships?
Immunovant's core assets originated from a licensing agreement with HanAll Biopharma of South Korea, entered into in December 2017. This agreement grants Immunovant rights to develop and commercialize anti-FcRn antibodies in certain territories. The firm has not publicly disclosed additional co-development partnerships with large pharmaceutical companies, choosing to maintain full control over its clinical programs while operating within the Roivant ecosystem.
What is Immunovant's clinical development timeline?
Immunovant's pivotal Phase 3 trial evaluating batoclimab in myasthenia gravis reported positive topline results in March 2024. In January 2025, the firm announced accelerated development for IMVT-1402, with plans to launch a registrational program by mid-2026. The company has indicated that IMVT-1402 will be developed across multiple autoimmune indications, with priority given to indications where the FcRn mechanism has already demonstrated clinical proof-of-concept.
Who makes final investment decisions on pipeline prioritization?
Pipeline prioritization is led by Chief Executive Officer Peter Salzmann, who has led Immunovant since its founding. The firm's board of directors, which includes representatives from Roivant Sciences, provides governance and strategic oversight. Given Immunovant's concentrated focus on anti-FcRn antibodies, resource allocation decisions center on indication selection and clinical development sequencing rather than broad portfolio management.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: